Abstract: The invention relates to a new process for producing useful intermediates for the manufacture of NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a g-amino-d-biphenyl-a-methylalkanoic acid, or acid ester, backbone, such as N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester or salt thereof.

Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, G, and Q are defined herein.

Abstract: This application relates to thiophene azo dyes for use as hueing agents, laundry care compositions comprising such thiophene azo dyes, processes for making such thiophene azo dyes, and laundry care compositions and methods of using the same. The thiophene azo dyes contain a formally charged moiety and are generally comprised of at least two components: at least one chromophore component and at least one polymeric component. Suitable chromophore components generally fluoresce blue, red, violet, or purple color when exposed to ultraviolet light, or they may absorb light to reflect these same shades. These thiophene azo dyes are advantageous in providing a hueing effect, for example, a whitening effect to fabrics, while not building up over time and causing undesirable blue discoloration to the treated fabrics. The thiophene azo dyes are also generally stable to bleaching agents used in laundry care compositions.

Abstract: The present invention provides a solid pharmaceutical composition containing compound (I) having an angiotensin II receptor antagonistic action and defined in the specification and a pH control agent, which composition is superior in the stability and dissolution property of compound (I).

Abstract: The present invention discloses a metal nickel-imidazolate chiral nano clathrate complex and preparation method thereof. The new type of metal nickel-imidazolate chiral nano clathrate complex of the present invention has the following chemical formula: [Ni14(Im)24].4NO3, in which Im is N-1-methyl-(4-imidazole) methylene imine. The complex can be obtained directly from a reaction of starting materials or prepared through first initiating a reaction between the compound ligand Im and a nickel salt under solvothermal conditions, and the complex obtained is of higher purity. The nano clathrate complex of the present invention has single chirality, and higher thermal stability, and thus has potential application in chiral catalytic materials.

Abstract: The present invention discloses zeolite metal bis(imidazole) coordination polymers and preparation method thereof. The new class of zeolite coordination polymers of the present invention is a chemical compound with the following general chemical formula {[M(BIm)]×xDMF×yC2H6O×zH2O}?, in which when M=Zn, x=0.9, y=0, z=0; when M=Cu, x=1.2, y=0, z=0; when M=Mn, x=2.0, y=0, z=0; when M=Ni, x=0.4, y=1.2, z=1.0, BIm is 1,2-bis((5H-imidazol-4-yl)methylene)hydrazine, DMF is N,N-dimethyl formamide, H2O is water. A solvothermal method or slow diffusion is used on the compounds to obtain crystals of high purity. The coordination polymers of the present invention have good thermal stability, and have strong adsorption performance for CO2 under conditions of 0° C. and normal pressure as adsorbent materials.

Abstract: The invention relates to crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one, processes for the preparation thereof, pharmaceutical compositions containing said crystalline forms, and their use as compounds improving vascular function and as immunomodulating agents, either alone or in combination with other active compounds or therapies.

Abstract: The invention relates to a new process for producing NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a ?-amino-?-biphenyl-?-methylalkanoic acid, or acid ester, backbone. In detail, the new processes, according to the present invention, are ultimately related to the synthesis of intermediates to prepare the above NEP inhibitors, namely compounds according to formula (1), or salt thereof, wherein R1 and R2 are, independently of each other, hydrogen or a nitrogen protecting group, and R3 is a carboxyl group or an ester group, preferably carboxyl group or alkyl ester.

Abstract: To provide methods of forming fluorescence-producing organometallic complexes which can ensure high durability when used in organic electroluminescence devices. For example, a compound 106 is prepared in accordance with the following reaction scheme.

Abstract: The present invention uses a nitrogen-containing organic compound to be reacted with an alkyl sultone to obtain a zwitterion compound. The zwitterion compound is reacted with a heteropoly acid (HPA) to obtain an ionic liquid HPA (IL-HPA). The IL-HPA is used for acetylation of polyol and HOAc for obtaining polyol acetate. The IL used in the reaction can be recycled. Thus, problems of product separation, waste acid handling, and corrosion of facilities are solved and production through esterification is improved with a green catalysis.

Abstract: The invention relates to novel trifluoromethyl-oxadiazole derivatives of formula (I), and pharmaceutically acceptable salts thereof, (I) in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, pharmaceutical combinations thereof, and their use as medicaments, particularly for the treatment of neurodegeneration, muscle atrophy or metabolic syndrome via inhibition of HDAC4.

Abstract: The invention relates to methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid (1,3PDS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 1,3PDS, either in vitro or in vivo. The invention also relates to sulfonate ester prodrugs of 1,3PDS as well as Gemini dimmers and oligomers of 1,3PDS for the prevention or treatment of associated diseases and conditions.

Abstract: Novel biaryl compounds with phosphodiesterase inhibitory activity of general formula (I) below, wherein R1, R2, R3, X, Y, Z1, Z2, Z3, and Z4 have the meanings defined herein, as well as their use as therapeutic agents in the treatment of inflammatory diseases and conditions are described herein.

Abstract: Provided herein are new 3,5-disubstituted-1,3,4-oxadiazol-2(3H)-ones and derivatives thereof that exhibit nematicidal activity and are useful, for example, in methods for the control of unwanted nematodes.

Abstract: The present disclosure relates to a new diphosphonate compound, and the method to prepare the above new diphosphonate compound. The new diphosphonate compound exhibits an activity in inhibiting osteoclast equivalent to alendronate sodium, and a higher activity in affecting the proliferation of osteoplast than the positive control compounds, but the positive control exhibits a weaker effect on osteoblast proliferation. In experimental examples, an administration schedule for the diphosphonate compound is provided.

Abstract: A compound includes at least one group Q and at least one group A linked together by at least one “spacer” group Sp, in which: group Q includes a dipole containing at least one nitrogen atom, preferably a nitrile oxide, nitrone, or nitrile imine function; group A contains at least one nitrogen atom, and is preferably an imidazolidinyl, ureyl, bis-ureyl, ureido-pyrimidyl, and triazolyl group; and Sp is an atom or a group of atoms forming a link between Q and A, preferably, a linear, branched or cyclic hydrocarbon-based optionally substituted chain, and may contain one or more aromatic radicals and/or heteroatoms. The compound may react with an unsaturated polymer forming a covalent bond with the polymer. The compound is useful for providing good interaction between fillers and polymers by establishing labile, non-covalent bonds between the polymer chains and the filler, thereby limiting processing problems.

Abstract: In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, R7, R8, Z, X, b, and c are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are nitric oxide donors and have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

Abstract: Methods are provided for identifying molecules that can be used to positively and negatively manipulate quorum-sensing-mediated communication to control bacterial behavior. Small-molecule antagonists that disrupt quorum-sensing-mediated activities are identified. Methods are provided for disrupting detection of acyl-homoserine lactone autoinducer in Gram-negative bacteria by contacting the bacteria with the antagonists. Methods of inhibiting quorum sensing-mediated activity in Gram-negative bacteria are provided wherein the activity is pathogenicity, bioluminescence, siderophore production, type III secretion, or metalloprotease production.

Abstract: A compound and method for treating myocilin glaucoma using a selective Grp94 inhibitor is presented. Clearance of mutant myocilin can be promoted by selectively targeting the endoplasmic reticulum (ER) chaperone Grp94 using siRNA knockdown or small molecule inhibitors. Grp94 contributes to the intracellular accumulation of mutant myocilin. Tailored treatments aimed at disrupting the Grp94/mutant myocilin interaction can be used as a new therapeutic strategy for myocilin glaucoma. The inventors developed a compound having a general backbone structure of geldanamycin (GDA) and radicicol (RDC) in which a more hydrophobic surrogate of the quinone in GDA is linked to the resorcinol in RDC through a cis-amide bioisostere.

Abstract: The present invention provides a compound of Formula (X) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.